CIN '2007 - 4º CONGRESO DE NEFROLOGIA EN INTERNET
Rituximab and antineutrophil cytoplasmic antibody-associated vasculitis, future therapeutic hope?
Dr Christopher Wong
Department of Nephrology, Aintree University Hospital, Lower Lane, Liverpool
Abstract
Despite cyclophosphamide and steroids being the mainstay of treatment for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), up to 10% of cases remain refractory [1]. For these refractory patients and those intolerant of the conventional therapy, recent successful report of response with rituximab (RIT) provide promising future therapeutic hope.Comentarios :